{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:51:31Z","timestamp":1793317891077,"version":"4.5.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T00:00:00Z","timestamp":1527033600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","award":["102521\/Z\/13\/Z"],"award-info":[{"award-number":["102521\/Z\/13\/Z"]}],"id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["102521\/Z\/13\/Z"],"award-info":[{"award-number":["102521\/Z\/13\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2015\/23898-8"],"award-info":[{"award-number":["2015\/23898-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01132","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T00:59:25Z","timestamp":1527037165000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":187,"title":["Blockade of MIF\u2013CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma"],"prefix":"10.3389","volume":"9","author":[{"given":"Carlos R.","family":"Figueiredo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo A.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Mousdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro T.","family":"Resende-Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Ireland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Girola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo L. O. R.","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Polonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz R.","family":"Travassos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Mielgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/cgt.2016.56","article-title":"Combinatorial immunotherapy for melanoma","volume":"24","author":"George","year":"2017","journal-title":"Cancer Gene Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000351713","article-title":"Metastatic volume: an old oncologic concept and a new prognostic factor for stage IV melanoma patients","volume":"227","author":"Panasiti","year":"2013","journal-title":"Dermatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Network","year":"2015","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s11912-009-0053-z","article-title":"Betting on immunotherapy for melanoma","volume":"11","author":"Sznol","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.immuni.2011.07.010","article-title":"CD8(+) T cells: foot soldiers of the immune system","volume":"35","author":"Zhang","year":"2011","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nature01006","article-title":"Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane","volume":"418","author":"Chow","year":"2002","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1158\/1078-0432.CCR-14-1554","article-title":"BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth","volume":"21","author":"Wang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.09.021","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.1158\/0008-5472.CAN-16-1201","article-title":"Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors","volume":"76","author":"Ireland","year":"2016","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/ncb3340","article-title":"Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis","volume":"18","author":"Nielsen","year":"2016","journal-title":"Nat Cell Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5483\/BMBRep.2013.46.3.036","article-title":"Impact of tumour associated macrophages in pancreatic cancer","volume":"46","author":"Mielgo","year":"2013","journal-title":"BMB Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fimmu.2012.00274","article-title":"Regulatory dendritic cells: there is more than just immune activation","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fimmu.2013.00082","article-title":"Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells","volume":"4","author":"Hubo","year":"2013","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nrc3253","article-title":"Tumour immunology: dendritic cell switch","volume":"12","author":"Seton-Rogers","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3109\/08830181003602515","article-title":"Immunogenic versus tolerogenic dendritic cells: a matter of maturation","volume":"29","author":"Tisch","year":"2010","journal-title":"Int Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ncb3169","article-title":"Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver","volume":"17","author":"Costa-Silva","year":"2015","journal-title":"Nat Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e8187","DOI":"10.1371\/journal.pone.0008187","article-title":"Antibody complementarity-determining regions (CDRs): a bridge between adaptive and innate immunity","volume":"4","author":"Gabrielli","year":"2009","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fmicb.2012.00190","article-title":"Antibody peptide based antifungal immunotherapy","volume":"3","author":"Magliani","year":"2012","journal-title":"Front Microbiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"14310","DOI":"10.1038\/srep14310","article-title":"A novel microtubule de-stabilizing complementarity-determining region C36L1 peptide displays antitumor activity against melanoma in vitro and in vivo","volume":"5","author":"Figueiredo","year":"2015","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.peptides.2014.06.007","article-title":"Anti-tumor activities of peptides corresponding to conserved complementary determining regions from different immunoglobulins","volume":"59","author":"Figueiredo","year":"2014","journal-title":"Peptides"},{"key":"B26","doi-asserted-by":"publisher","first-page":"14912","DOI":"10.1074\/jbc.M111.322362","article-title":"\u03b2-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumor cells and is protective against metastatic melanoma","volume":"287","author":"Arruda","year":"2012","journal-title":"J Biol Chem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1593\/tlo.09316","article-title":"Differential antitumor effects of IgG and IgM monoclonal antibodies and their synthetic complementarity-determining regions directed to new targets of B16F10-Nex2 melanoma cells","volume":"3","author":"Dobroff","year":"2010","journal-title":"Transl Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.2174\/092986709788453104","article-title":"Antibodies as crypts of antiinfective and antitumor peptides","volume":"16","author":"Magliani","year":"2009","journal-title":"Curr Med Chem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1158\/2326-6066.CIR-15-0070-T","article-title":"MIF is necessary for late-stage melanoma patient MDSC immune suppression and differentiation","volume":"4","author":"Yaddanapudi","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.4049\/jimmunol.1201650","article-title":"Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor","volume":"190","author":"Yaddanapudi","year":"2013","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/eji.201243162","article-title":"Partial MHC class II constructs inhibit MIF\/CD74 binding and downstream effects","volume":"43","author":"Benedek","year":"2013","journal-title":"Eur J Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.4049\/jimmunol.1303118","article-title":"HLA-DR\u03b11 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis","volume":"192","author":"Meza-Romero","year":"2014","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.4049\/jimmunol.179.11.7577","article-title":"Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking","volume":"179","author":"Xu","year":"2007","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"W423","DOI":"10.1093\/nar\/gks398","article-title":"PepSite: prediction of peptide-binding sites from protein surfaces","volume":"40","author":"Trabuco","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.1093\/emboj\/17.23.6812","article-title":"Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii","volume":"17","author":"Jasanoff","year":"1998","journal-title":"EMBO J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jmb.2008.10.032","article-title":"Collective motions in glucosamine-6-phosphate synthase: influence of ligand binding and role in ammonia channelling and opening of the fructose-6-phosphate binding site","volume":"385","author":"Floquet","year":"2009","journal-title":"J Mol Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jmb.2011.05.034","article-title":"A concerted mechanism for opening the GDP binding pocket and release of the nucleotide in hetero-trimeric G-proteins","volume":"411","author":"Louet","year":"2011","journal-title":"J Mol Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1038\/s41388-017-0115-x","article-title":"Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer","volume":"37","author":"Ireland","year":"2018","journal-title":"Oncogene"},{"key":"B39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12967-015-0736-1","article-title":"Future perspectives in melanoma research: meeting report from the \u201cMelanoma Bridge\u201d: Napoli, December 3rd-6th 2014","volume":"13","author":"Ascierto","year":"2015","journal-title":"J Transl Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","article-title":"T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy","volume":"4","author":"Melero","year":"2014","journal-title":"Cancer Discov"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.4155\/fmc.12.75","article-title":"Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides","volume":"4","author":"Roxin","year":"2012","journal-title":"Future Med Chem"},{"key":"B42","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1006\/bbrc.1999.1584","article-title":"High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis","volume":"264","author":"Shimizu","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"B43","doi-asserted-by":"publisher","first-page":"710","DOI":"10.4049\/jimmunol.165.2.710","article-title":"Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells","volume":"165","author":"Repp","year":"2000","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.gdata.2015.12.025","article-title":"MIF inhibition reverts the gene expression profile of human melanoma cell line-induced MDSCs to normal monocytes","volume":"7","author":"Waigel","year":"2016","journal-title":"Genom Data"},{"key":"B45","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1186\/1471-2407-14-630","article-title":"Macrophage migration inhibitory factor engages PI3K\/Akt signalling and is a prognostic factor in metastatic melanoma","volume":"14","author":"Oliveira","year":"2014","journal-title":"BMC Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"172","DOI":"10.21037\/atm.2016.05.04","article-title":"Uveal melanoma as a target for immune-therapy","volume":"4","author":"Oliva","year":"2016","journal-title":"Ann Transl Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00011-016-0995-1","article-title":"The biological function and significance of CD74 in immune diseases","volume":"66","author":"Su","year":"2017","journal-title":"Inflamm Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11011-016-9798-x","article-title":"Predicted structure of MIF\/CD74 and RTL1000\/CD74 complexes","volume":"31","author":"Meza-Romero","year":"2016","journal-title":"Metab Brain Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"6246","DOI":"10.1038\/onc.2016.160","article-title":"MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis","volume":"35","author":"Ghoochani","year":"2016","journal-title":"Oncogene"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.bbamcr.2016.03.026","article-title":"The multifaceted roles of the invariant chain CD74 \u2013 more than just a chaperone","volume":"1863","author":"Schr\u00f6der","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B51","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cyto.2006.01.006","article-title":"Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation","volume":"33","author":"Yan","year":"2006","journal-title":"Cytokine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imm.12123","article-title":"Kinase AKT controls innate immune cell development and function","volume":"140","author":"Zhang","year":"2013","journal-title":"Immunology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","article-title":"Melanoma","volume":"1","author":"Schadendorf","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41598-017-01000-2","article-title":"Indicators of responsiveness to immune checkpoint inhibitors","volume":"7","author":"Shields","year":"2017","journal-title":"Sci Rep"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3389\/fimmu.2017.01215","article-title":"Coinhibitory receptor expression and immune checkpoint blockade: maintaining a balance in CD8+ T cell responses to chronic viral infections and cancer","volume":"8","author":"Okoye","year":"2017","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1038\/onc.2017.1","article-title":"Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy","volume":"36","author":"Castro","year":"2017","journal-title":"Oncogene"},{"key":"B59","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/ijc.27736","article-title":"Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma","volume":"132","author":"Funamizu","year":"2013","journal-title":"Int J Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.4049\/jimmunol.1201161","article-title":"Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment","volume":"189","author":"Simpson","year":"2012","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bpa.12194","article-title":"MIF receptor CD74 is restricted to microglia\/macrophages, associated with a M1-polarized immune milieu and prolonged patient survival in gliomas","volume":"25","author":"Zeiner","year":"2015","journal-title":"Brain Pathol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1158\/1535-7163.MCT-12-0988","article-title":"Human anti-macrophage migration inhibitory factor antibodies inhibit growth of human prostate cancer cells in vitro and in vivo","volume":"12","author":"Hussain","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"36541","DOI":"10.1074\/jbc.C500243200","article-title":"ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis","volume":"280","author":"Al-Abed","year":"2005","journal-title":"J Biol Chem"},{"key":"B64","doi-asserted-by":"publisher","first-page":"8730","DOI":"10.4049\/jimmunol.177.12.8730","article-title":"Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells","volume":"177","author":"Meyer-Siegler","year":"2006","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1517\/13543780903463854","article-title":"Milatuzumab \u2013 a promising new immunotherapeutic agent","volume":"19","author":"Berkova","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"B66","doi-asserted-by":"publisher","first-page":"6802","DOI":"10.1158\/0008-5472.CAN-16-0427","article-title":"Modulation of immune checkpoints and graft-versus-leukemia in allogeneic transplants by antagonizing vasoactive intestinal peptide signaling","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"11760","DOI":"10.1002\/anie.201506225","article-title":"Blocking of the PD-1\/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy","volume":"54","author":"Chang","year":"2015","journal-title":"Angew Chem Int Ed Engl"},{"key":"B68","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1158\/2326-6066.CIR-17-0035","article-title":"Peptide blocking of PD-1\/PD-L1 interaction for cancer immunotherapy","volume":"6","author":"Li","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jaut.2012.08.004","article-title":"A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance","volume":"40","author":"Vandenbark","year":"2013","journal-title":"J Autoimmun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01132\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T00:59:43Z","timestamp":1527037183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01132\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,23]]},"references-count":69,"alternative-id":["10.3389\/fimmu.2018.01132"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01132","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/248807","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,23]]},"article-number":"1132"}}